Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by IFM Investors Pty Ltd

IFM Investors Pty Ltd increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,372 shares of the life sciences company's stock after purchasing an additional 3,309 shares during the quarter. IFM Investors Pty Ltd's holdings in Illumina were worth $2,568,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Freedom Investment Management Inc. lifted its holdings in Illumina by 3.7% during the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock valued at $382,000 after purchasing an additional 101 shares during the last quarter. Personal CFO Solutions LLC grew its stake in Illumina by 9.2% during the fourth quarter. Personal CFO Solutions LLC now owns 1,789 shares of the life sciences company's stock worth $239,000 after purchasing an additional 150 shares during the period. GC Wealth Management RIA LLC grew its stake in Illumina by 9.5% in the fourth quarter. GC Wealth Management RIA LLC now owns 1,783 shares of the life sciences company's stock valued at $238,000 after acquiring an additional 154 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Illumina by 16.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,108 shares of the life sciences company's stock valued at $148,000 after buying an additional 156 shares during the last quarter. Finally, Signaturefd LLC boosted its position in Illumina by 10.4% in the fourth quarter. Signaturefd LLC now owns 1,880 shares of the life sciences company's stock worth $251,000 after purchasing an additional 177 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Evercore ISI increased their target price on shares of Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research note on Tuesday. JPMorgan Chase & Co. reduced their price objective on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Morgan Stanley cut their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Stephens reaffirmed an "overweight" rating and issued a $105.00 target price on shares of Illumina in a report on Tuesday, May 20th. Finally, Citigroup reaffirmed a "sell" rating and issued a $80.00 price target (down previously from $85.00) on shares of Illumina in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $127.16.

Insider Buying and Selling at Illumina

In other news, CFO Ankur Dhingra purchased 6,100 shares of the business's stock in a transaction on Monday, May 12th. The shares were acquired at an average cost of $81.21 per share, with a total value of $495,381.00. Following the completion of the acquisition, the chief financial officer owned 24,906 shares of the company's stock, valued at $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.17% of the company's stock.

Illumina Trading Down 2.0%

Shares of NASDAQ ILMN traded down $1.97 during midday trading on Wednesday, hitting $97.31. 671,730 shares of the company traded hands, compared to its average volume of 2,144,477. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. The stock has a 50-day moving average price of $85.88 and a 200 day moving average price of $96.96. The firm has a market cap of $15.40 billion, a P/E ratio of -16.06, a P/E/G ratio of 1.91 and a beta of 1.36.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. Illumina's revenue was down 1.4% compared to the same quarter last year. During the same period last year, the firm posted $0.98 earnings per share. As a group, analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.